Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab vs Chemotherapy in First-Line Advanced NSCLC with PD-L1 >= 50%
NCT03088540Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2017
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 24
01
Overview
A Phase 3 trial of cemiplimab in non-small cell lung carcinoma (NSCLC), sponsored by Regeneron Pharmaceuticals. Started May 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT03088540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088540.